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Since our relaunch in early 2008  [1],  our journal experienced many changes and has 
developed very, very positively. In this short summary we will give you selected snapshots 
of what has happened, what is going on, and what is yet to come. 
Online version (‘open access’) and editorial work 
While we completely modernized the print version with volume 79 (2011), and while it will 
continue to meet the needs of some of our readers, University libraries, scientific 
databases and indexing companies, the main focus lies on our online version on 
www.scipharm.at. Due to the generous support of our parent organizations, the Austrian 
Chamber of Pharmacists (ÖAK,  Österreichische Apothekerkammer) and the Austrian 
Pharmaceutical Society (ÖPhG, Österreichische Pharmazeutische Gesellschaft), the 
electronic version of our journal can still be accessed on our homepage without any 
subscription or registration barriers. Such an open-access model has become more and 
more frequent in scientific publishing during the last decade. However, it is quite unusual 
neither readers (‘open access’) nor  authors (no publishing fees) are charged, and this 
holds true for Scientia Pharmaceutica. This fact guarantees the editorial independence of 
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Fig. 1.  Full-text downloads (PDF) of articles published on www.scipharm.at  
(abstract-only-views are not included) 
The popularity of our online version is still increasing. Figure 1, which shows the monthly 
full text downloads from our homepage, documents this. Please note, these incredible 
numbers do not include ‘abstract only views’ or the many views on internet sites that have 
hosted the content of our journal. Of course, these positive circumstances, which ensure 
that each paper published receives the best possible dissemination and publicity, attract 
many researchers from around the world as potential authors. Consequently, this led—and 
still leads—to an increased number of submissions (approximately 400 manuscripts are 
expected for 2011!).  
 
Fig. 2.   Number of published reviews, research papers, and short communications.  
* based on 3 of 4 issues. 
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However, because of the expansion of our editorial team—Franz GABOR and Reinhard 
LÄNGER joined as scientific editors and many new members joined our scientific advisory 
board (www.scipharm.at/board/)—we are able administrate the rapid peer review process 
for all submissions. Nevertheless, because ‘quality comes first’ at Sci Pharm, only the best 
of the numerous submissions are selected by our expert editors for publication, with the 
highly appreciated help of many referees. Although we do not have a specific page or 
paper limit for publication, we are currently publishing around 50–60 papers each year 
(see figure 2). While comparing the number of submissions with the number of published 
articles, it is evident Sci Pharm applies a rigorous peer review for each paper to maintain 
the high scientific standards (see the current rejection rate of approximately 85% in 
figure 3).  
 
Fig. 3.   Rejection Rate 
Special Issue: Novel Biogene Sesquiterpenes (NBST) 
Under the guidance of five internationally renowned experts (Prof. Dr. Yoshinori Asakawa, 
Tokushima, Japan;  Prof.  Dr. Franz Bucar, Graz, Austria; Prof. Dr. Biswanath Das, 
Hyderabad, India; Prof. Dr. De-An Guo, Shanghai, People's Republic of China; Prof. Dr. 
Andrew Marston, Bloemfontein, Republic of South Africa) a special issue on sesqui-
terpenes has been scheduled for 2012. The editors are looking forward to receiving your 
high-quality contributions. Further information including the official call-for-papers can be 
found online >>> www.scipharm.at/nbst/ 
Indexing & Impact factor 
Many indexing services have noticed the positive transformation of our journal which has 
resulted in an increased abstracting of the articles. Through the implementation of the 
digital object identifier (DOI-CrossRef) for each published article, a crosslinking from many 
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of those databases to the full text on the Sci Pharm webpage is also possible. For 
example, the Chemical Abstracts Service reclassified Sci Pharm as Core journal, and 
EBSCO, CAB Abstracts, ProQuest, and many others have incorporated Sci Pharm into 
their products. Sci Pharm achieved one of its principal goals through its inclusion to 
PubMed, the well-known second-to-none database for biomedical literature. Also, all 
articles are placed into PubMed’s open-access archive PubMed Central. 
Currently, the journal is applying for inclusion in Thomson Reuter’s database ‘Journal 
Citation Reports
®’, which is better known for its associated journal metric the Impact Factor 
(IF)—a measure reflecting the average number of citations to  articles published in  a 
specific journal. You can help accelerate this process by recommending Sci Pharm on 
Thomson Reuter’s webpage http://science.thomsonreuters.com/info/journalrec/. However, 
even for journals that have not been tracked for enough time to have an Impact Factor or 
are not yet tracked by Thomson Reuters  (ISI), it is possible to calculate an  unofficial 
Impact Factor based on Thomson Reuter’s ‘Web of Science’ database, which is shown in 
figure 4. 
 
Fig. 4.  Unofficial impact factors for Scientia Pharmaceutica 
Please note that the journal’s relaunch in 2008 is not evident before 2010 in this chart 
(because of the calculation algorithm of the IF based on the past two years). Indeed, the IF 
2010 doubled compared to the nearly constant IF in the previous years. It is noteworthy 
that for 2011 a significantly further increased IF of about 0.7–0.9 is expected. 
Citation Award 
This summer for the first time, Sci Pharm will grant an award to the author(s) of the most 
cited paper published in the journal. According to Thomson Reuter’s ‘Web of Knowledge’ 
database, all articles of 2009 were analyzed and the article with the most citations in 2010 
qualified for this prize [2]:  
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Biotransformation of Artemisinin Mediated through Fungal Strains for Obtaining 
Derivatives with Novel Activities, by S. Srivastava, S. Luqman, A. Fatima, M. P. Darokar, 
A. S Negi, J. K. Kumar, K. Shanker, C. S. Chanotiya, S. Tandon, S. P. S. Khanuja, which 
was published in Sci Pharm, Volume 77, Issue 1 (2009), Pages 87–95 [3].  
 
Fig. 5.  This year’s recipient, M. P. Darokar from Lucknow, India, received his ‘Citation 
Award’ certificate together with the 1 ounce Vienna Philharmonic Coin. This 
renowned Austrian coin shows the world famous Vienna Philharmonic 
Orchestra. It was coined in 2009, the year when the article was published. 
Congratulations! 
Sci Pharm plans to repeat this citation award in future years. 
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